Literature DB >> 23539722

Variation in the management of thyroid cancer.

Megan R Haymart1, Mousumi Banerjee, Di Yang, Andrew K Stewart, James C Sisson, Ronald J Koenig, Gerard M Doherty, Jennifer J Griggs.   

Abstract

CONTEXT: Little is known about practice patterns in thyroid cancer, a cancer that is increasing in incidence.
OBJECTIVE: We sought to identify aspects of thyroid cancer management that have the greatest variation. DESIGN/SETTING/PARTICIPANTS: We surveyed 944 physicians involved in thyroid cancer care from 251 hospitals affiliated with the US National Cancer Database. Physicians were asked questions in the following four domains: thyroid surgery, radioactive iodine use, thyroid hormone replacement postsurgery, and long-term thyroid cancer management. We calculated the ratio of observed variation to hypothetical maximum variation under the assumed distribution of the response. Ratios closer to 1 indicate greater variation.
RESULTS: We had a 66% response rate. We found variation in multiple aspects of thyroid cancer management, including the role of central lymph node dissections (variation, 0.99; 95% confidence interval [CI], 0.98-1.00), the role of pretreatment scans before radioactive iodine treatment (variation, 1.00; 95% CI, 0.98-1.00), and all aspects of long-term thyroid cancer management, including applications of ultrasound (variation, 0.97; 95% CI, 0.93-0.99) and radioactive iodine scans (variation, 0.99; 95% CI, 0.97-1.00). For the management of small thyroid cancers, variation exists in all domains, including optimal extent of surgery (variation, 0.91; 95% CI, 0.88-0.94) and the role of both radioactive iodine treatment (variation, 0.91; 95% CI, 0.89-0.93) and suppressive doses of thyroid hormone replacement (variation, 1.00; 95% CI, 0.99-1.00).
CONCLUSION: We identified areas of variation in thyroid cancer management. To reduce the variation and improve the management of thyroid cancer, there is a need for more research and more research dissemination.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23539722      PMCID: PMC3644603          DOI: 10.1210/jc.2012-3355

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

1.  Managing patients with a preoperative diagnosis of AJCC/UICC stage I (T1N0M0) papillary thyroid carcinoma: East versus West, whose policy is best?

Authors:  Ian D Hay
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

2.  Total thyroidectomy followed by postsurgical remnant ablation may improve cancer specific survival in differentiated thyroid carcinoma.

Authors:  Suhail A R Doi; Jessica M Engel; Adedayo A Onitilo
Journal:  Clin Nucl Med       Date:  2010-06       Impact factor: 7.794

3.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

4.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

5.  Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005.

Authors:  Amy Y Chen; Ahmedin Jemal; Elizabeth M Ward
Journal:  Cancer       Date:  2009-08-15       Impact factor: 6.860

6.  Extent of surgery affects survival for papillary thyroid cancer.

Authors:  Karl Y Bilimoria; David J Bentrem; Clifford Y Ko; Andrew K Stewart; David P Winchester; Mark S Talamonti; Cord Sturgeon
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

7.  Risks and adequacy of an optimized surgical approach to the primary surgical management of papillary thyroid carcinoma treated during 1999-2006.

Authors:  Clive S Grant; John M Stulak; Geoffrey B Thompson; Melanie L Richards; Carl C Reading; Ian D Hay
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

Review 8.  What is the optimal initial treatment of low-risk papillary thyroid cancer (and why is it controversial)?

Authors:  Ernest L Mazzaferri
Journal:  Oncology (Williston Park)       Date:  2009-06       Impact factor: 2.990

9.  Utilization of total thyroidectomy for papillary thyroid cancer in the United States.

Authors:  Karl Y Bilimoria; David J Bentrem; John G Linn; Andrew Freel; Jen Jen Yeh; Andrew K Stewart; David P Winchester; Clifford Y Ko; Mark S Talamonti; Cord Sturgeon
Journal:  Surgery       Date:  2007-11-05       Impact factor: 3.982

10.  The relationship between extent of thyroid cancer surgery and use of radioactive iodine.

Authors:  Megan R Haymart; Mousumi Banerjee; Di Yang; Andrew K Stewart; Gerard M Doherty; Ronald J Koenig; Jennifer J Griggs
Journal:  Ann Surg       Date:  2013-08       Impact factor: 12.969

View more
  31 in total

1.  Variation in the Echocardiographic Surveillance of Primary Mitral Regurgitation.

Authors:  Varsha K Tanguturi; Michael K Hidrue; Michael H Picard; Steven J Atlas; Jeffrey B Weilburg; Timothy G Ferris; Katrina Armstrong; Jason H Wasfy
Journal:  Circ Cardiovasc Imaging       Date:  2017-08       Impact factor: 7.792

Review 2.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

3.  Worry in Thyroid Cancer Survivors with a Favorable Prognosis.

Authors:  Maria Papaleontiou; David Reyes-Gastelum; Brittany L Gay; Kevin C Ward; Ann S Hamilton; Sarah T Hawley; Megan R Haymart
Journal:  Thyroid       Date:  2019-07-25       Impact factor: 6.568

4.  Inappropriate Use of Radioactive Iodine for Low-Risk Papillary Thyroid Cancer Is Most Common in Regions with Poor Access to Healthcare.

Authors:  Jennifer L Marti; Louise Davies; Megan R Haymart; Benjamin R Roman; R Michael Tuttle; Luc G T Morris
Journal:  Thyroid       Date:  2015-05-28       Impact factor: 6.568

Review 5.  Multicriteria decision analysis in oncology.

Authors:  Georges Adunlin; Vakaramoko Diaby; Alberto J Montero; Hong Xiao
Journal:  Health Expect       Date:  2014-03-17       Impact factor: 3.377

Review 6.  Differentiated thyroid cancer-personalized therapies to prevent overtreatment.

Authors:  Markus Luster; Theresia Weber; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2014-07-01       Impact factor: 43.330

7.  Radioactive iodine in differentiated thyroid cancer: a national database perspective.

Authors:  Ryan K Orosco; Timon Hussain; Julia E Noel; David C Chang; Chrysoula Dosiou; Erik Mittra; Vasu Divi; Lisa A Orloff
Journal:  Endocr Relat Cancer       Date:  2019-10       Impact factor: 5.678

8.  Papillary thyroid microcarcinoma: decision-making, extent of surgery, and outcomes.

Authors:  Amanda K Price; Reese W Randle; David F Schneider; Rebecca S Sippel; Susan C Pitt
Journal:  J Surg Res       Date:  2017-06-21       Impact factor: 2.192

9.  Cost-effectiveness analysis of papillary thyroid cancer surveillance.

Authors:  Laura Y Wang; Benjamin R Roman; Jocelyn C Migliacci; Frank L Palmer; R Michael Tuttle; Ashok R Shaha; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Cancer       Date:  2015-08-17       Impact factor: 6.860

10.  Effectiveness of routine ultrasonographic surveillance of patients with low-risk papillary carcinoma of the thyroid.

Authors:  Laura Y Wang; Benjamin R Roman; Frank L Palmer; R Michael Tuttle; Ashok R Shaha; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Surgery       Date:  2015-12-31       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.